Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

ies or other circumstances, or matters outside of the company's control between the date of this release and the date that its Form 10-K for the year ended Dec. 31, 2008 is filed with the SEC could potentially result in adjustments to reported earnings. The company undertakes no obligation to update statements herein for revisions or changes after the date of this release.

                             Mylan Inc. and Subsidiaries
                  Condensed Consolidated Statements of Operations
                 (Unaudited; in thousands, except per share amounts)

                       Three Months Ended            Twelve Months Ended
                   December 31,   December 31,   December 31,   December 31,
                       2008           2007           2008           2007
                  -------------  -------------  -------------  -------------

    Net revenues      $1,190,557     $1,147,834     $4,631,237     $2,646,643
    Other revenues        12,598          7,515        506,348         19,380
                          ------          -----        -------         ------
         Total
          revenues     1,203,155      1,155,349      5,137,585      2,666,023

    Cost of sales        808,502        799,251      3,067,364      1,556,728
                         -------        -------      ---------      ---------
    Gross profit         394,653        356,098      2,070,221      1,109,295
                         -------        -------      ---------      ---------

    Operating expenses:
    Research and
     development          77,897         80,766        317,217        182,911
    Acquired in-
     process
     research
     and development           -      1,269,036              -      1,416,036
    Impairment
     loss on
     goodwill                  -              -        385,000              -
    Selling, general
     and administrative  265,628        275,703      1,053,
'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , October 27, 2014 ... to produce, exhibit and sell its artificial "lower ... impeach their patent.      (Photo: ... years of fighting, the definitive judgement has arrived: ... produces innovative and accessible hi-tech prostheses with composite ...
(Date:10/27/2014)... 2014 New Q4-2014 incentives help ... an industry leading unified communication and collaboration provider, ... to deliver cloud-based audio and web/video conferencing solutions ... With SoundConnect’s Q4 incentive partners will ... web conferencing licenses sold, now through December 31st, ...
(Date:10/27/2014)... Janssen Biotech, Inc. and the Crohn,s ... the launch of Get Your Full ... designed to provide resources for people living with ... of nutrition and appropriate therapy in managing IBD. ... with this release, please click: http://www.multivu.com/players/English/7261131-janssen-ccfa-get-your-full-course-for-ibd-wellness-with-sunny-anderson/ ...
(Date:10/25/2014)... 2014 The report “Adipic Acid ... Geography - Global Trends & Forecast to 2019” ... to market drivers, opportunities, and trends in different ... 27 figures spread through 217 slides and in-depth ... & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2SoundConnect Unveils Q4 Partner Incentives 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... ET, LOS ANGELES, Aug. 31 Signalife, Inc. (Amex:,SGN), Lowell ... update since his matriculation into the Presidency,last month: 1. Dr. ... positions that were producing no revenue whatsoever and no ... Company, in his view. That was done ...
... Aug. 30 Cepheid (Nasdaq:,CPHD) will present at ... the Four Seasons Hotel, Boston, September 5 to ... Senior Vice President, Finance and,Chief Financial Officer, John ... on,September 7. The webcast, along with accompanying ...
... ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... subsidiary, YM BioSciences USA,Inc. ("YM-USA") has been cleared ... initiate a Phase II trial investigating nimotuzumab in ...
Cached Biology Technology:Signalife Provides Corporate Update 2Signalife Provides Corporate Update 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 3YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 4YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 5
(Date:10/29/2014)... 2014 — Cambridge, MA and Hebei, China — BGI ... high quality sequencing of the Jujube genome. Jujube is ... and the Jujube genome is particularly difficult to sequence ... factors. It is the first time that a genome ... study has been recently published in Nature ...
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... novel environment are linked to individual differences in ... completed at the University of Eastern Finland and ... study used novel, long-term observations of individual behaviour ... if behaviours predict the vulnerability to fishing in ... rearing environments. Based on the results, it ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3Fish 'personality' linked to vulnerability to angling 2
... is the primary component of nursery container substrates in ... widely used organic material is prompting researchers to investigate ... James E. Altland and Charles Krause of the USDA ... Development Center was designed to determine if ground switchgrass ...
... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
... the Braunschweiger Helmholtz-Zentrums fr Infektionsforschung (Helmholtz Center for ... bacterial communities are able to support the degradation ... collaboration of thirteen partners from nine countries. Research ... today at the HZI. The significance of this ...
Cached Biology News:Switchgrass proves viable as nursery container substrate 2Switchgrass proves viable as nursery container substrate 3Visualization of geographic patterns may predict spread of disease 2Improving the degradation of toxic hydrocarbons 2
RABBIT ANTI AMPHOTERIN...
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
... by R. Edwards (1996) • ... types of immunoassays, including RIA, ... and on the photoluminescent and ... information is also given on ...
... contains the basic components required for the ... and recombinant Feline IL-10 in cell culture ... materials to run ELISAs on approximately fifteen ... are met: The assay is run ...
Biology Products: